TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies Inc. has announced an investor conference call to update on its Phase II clinical study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. The study shows promising interim results, with a 64.3% complete response rate among patients. Financially, the company reported a slight decrease in revenue and an increase in net loss for the nine months ended September 30, 2025. Despite these financial challenges, Theralase continues to pursue funding opportunities to support its clinical and commercial objectives.
The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
Theralase Technologies’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis provides a neutral outlook, while valuation metrics highlight ongoing financial struggles. The absence of earnings call and corporate events data limits further insights.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecule compounds. Their primary objective is to achieve efficacy and safety in the destruction of cancer, bacteria, and viruses, while minimizing impact on surrounding healthy tissue.
Average Trading Volume: 109,040
Technical Sentiment Signal: Hold
Current Market Cap: C$53.98M
See more data about TLT stock on TipRanks’ Stock Analysis page.